1. Zinc N-acetyltaurinate of formula:
CH3\u2014CO\u2014NH\u2014CH2\u2014CH2\u2014SO3\u22122Zn2+
for use thereof in the treatment of prostate cancer.
2. The use of zinc N-acetyltaurinate of formula:
CH3\u2014CO\u2014NH\u2014CH2\u2014CH2\u2014SO3\u22122Zn2+
for preparing a medicament that is of use for treating prostate cancer.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1.-60. (canceled)
61. A (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.
62. A drug product comprising (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier.
63. The drug product of claim 62, wherein the drug product is suitable for oral administration.
64. The drug product of claim 62, wherein the drug product is in tablet form.
65. A crystalline (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt.
66. The crystalline salt of claim 65, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.
67. A drug product comprising a crystalline (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier.
68. The drug product of claim 67, wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.
69. The drug product of claim 67, wherein the drug product is suitable for oral administration.
70. The drug product of claim 67, wherein the drug product is in tablet form.